Telix Pharmaceuticals (NASDAQ:TLX) Shares Down 6.3% – Should You Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price was down 6.3% during mid-day trading on Tuesday . The company traded as low as $6.41 and last traded at $6.5150. Approximately 128,287 shares traded hands during trading, a decline of 36% from the average daily volume of 199,397 shares. The stock had previously closed at $6.95.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TLX. Citigroup restated a “buy” rating and issued a $22.50 target price (up from $22.00) on shares of Telix Pharmaceuticals in a report on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Finally, Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

Telix Pharmaceuticals Price Performance

The stock has a 50 day moving average of $7.48 and a 200-day moving average of $9.19. The company has a current ratio of 1.33, a quick ratio of 1.22 and a debt-to-equity ratio of 0.94.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $414.02 million during the quarter, compared to the consensus estimate of $421.50 million. Research analysts expect that Telix Pharmaceuticals Limited will post 0.24 EPS for the current year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers increased its position in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the fourth quarter worth approximately $89,000. OLD Mission Capital LLC purchased a new position in Telix Pharmaceuticals during the 4th quarter worth $111,000. Vident Advisory LLC purchased a new position in Telix Pharmaceuticals during the 4th quarter worth $204,000. Finally, IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.